Применение рекомбинантного эритропоэтина и ресвератрола для фармакологической коррекции ишемических повреждений миокарда

In this paper we present experimental evaluation of the use of recombinant eritropoietin and resveratrol while simulating myocardial infarction. It was perceived that inserting of recombinant eritropoietin and resveratrol considerably lowered the expansion of necrotic myocardial zone in the left ventricle of heart up to 13,2±0,3 % and 15,2±0,8 relatively (in comparison with a control group of animals). While this figure was 27,3±1,2 % in a control group. Preparatory blockade of ATP-sensitive potassium channels with glibenclamide, nonselective blockade of NO-synthase with L-NAME and selective blockade of inducible NO-synthase with aminoguanidine neutralized the effects of recombinant erythropoietin and resveratrol, thus showing the protective effect of recombinant erythropoietin. The protective effect of recombinant erythropoietin and resveratrol is due to the activation of nitric oxide synthesis and by the ATP-sensitive potassium channels, which proves the realization of their effects by mechanisms which is similar to the mechanism of the effects of distant ischemic preconditioning.